Bioxcel Therapeutics Logo
corporate website banner

Innovative Medicine Backed by the Power of AI

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, approaches.

Innovative Medicine
Backed by the
Power of AI

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.

Innovative Medicine
Backed by the Power of AI

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.

Our Approach to Drug Development

AI-based Drug Development

Our neuroscience and immuno-oncology franchises utilize our AI
approach to drug development.

Neuroscience

BXCL501-Neuroscience-image
BXCL501 is an investigational, proprietary, orally dissolving, thin film formulation of dexmedetomidine designed for the treatment of agitation and opioid withdrawal symptoms.

Immuno-Oncology

BXCL701-Immuno-Oncology-image
BXCL701 is an investigational, orally-administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

Latest News

May 20, 2022
BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment ConferenceVIEW RELEASE
May 09, 2022
BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational HighlightsVIEW RELEASE
May 05, 2022
BioXcel Therapeutics to Present at Three Upcoming Investor ConferencesVIEW RELEASE

Stock Information

BioXcel Therapeutics, Inc.

May 27, 2022 03:04 PM

MARKET/SYMBOL

BTAI

PRICE

12.26

CHANGE

0.72 (6.24%)